Can Hydrochlorothiazide Cause Diarrhea?

Hydrochlorothiazide (HCTZ) can cause diarrhea. It is a recognized gastrointestinal side effect listed in the drug’s prescribing information, though it tends to get less attention than the medication’s better-known effects on electrolytes and urination. Recent animal research has begun to reveal specific ways HCTZ alters the gut environment, offering a clearer picture of why some people develop digestive trouble after starting this widely prescribed blood pressure medication.

How Common Is Diarrhea on Hydrochlorothiazide?

Diarrhea is not the side effect most clinicians think of first when prescribing HCTZ. The conversations at the pharmacy counter usually center on dizziness, frequent urination, and the need to monitor potassium levels. But gastrointestinal complaints, including diarrhea, nausea, stomach cramps, and loss of appetite, have long been part of the drug’s adverse-event profile.

Pinning down an exact frequency is tricky, in part because clinical trials lump different gastrointestinal symptoms together, and post-marketing reports rely on patients and doctors voluntarily flagging problems. A large post-marketing safety study of a fixed-dose combination pill containing olmesartan, amlodipine, and hydrochlorothiazide recorded diarrhea among a cluster of less common adverse events reported in roughly 0.04% of patients.¹ That figure may understate the real-world rate. The study tracked a three-drug combination, so isolating HCTZ’s contribution to any individual symptom is difficult. And mild diarrhea, the kind that is more inconvenient than alarming, often goes unreported.

What most experienced prescribers will tell you is that mild gastrointestinal upset in the first few weeks of HCTZ use is not unusual, and for many people it fades as the body adjusts. When diarrhea persists, becomes watery, or is accompanied by significant cramping, that warrants a closer look, because the mechanisms behind it go beyond simple stomach irritation.

Why Hydrochlorothiazide Disrupts the Gut

Until recently, the assumption was that HCTZ-related diarrhea was a straightforward pharmacological nuisance, something the drug did to the GI tract in passing on its way to the kidneys. Newer research tells a more complicated story, one that involves the trillions of bacteria living in your intestines and the physical barrier that keeps gut contents where they belong.

A study in mice found that HCTZ treatment shifted the composition of gut bacteria in ways that are generally considered unfavorable. The drug led to an increase in Enterobacteriaceae, a bacterial family that includes several species associated with intestinal inflammation, while overall microbial diversity trended downward.² That shift matters because a diverse gut microbiome is generally more stable and more resistant to overgrowth by any one problematic species. When diversity drops, the conditions for digestive symptoms, including loose stools, improve.

The same study documented damage to the intestinal barrier itself. In HCTZ-treated mice, intestinal permeability increased significantly, and the expression of tight junction proteins in the ileum dropped. Tight junction proteins are the molecular rivets that hold neighboring gut lining cells together. When their levels fall, gaps open between cells, allowing substances that should stay in the intestinal lumen to leak into the bloodstream. This “leaky gut” phenomenon can trigger local inflammation and, in turn, changes in how quickly material moves through the digestive tract.²

Separate research in hypertensive rats confirmed and extended these findings. HCTZ specifically reduced populations of butyrate-producing bacteria.³ Butyrate is a short-chain fatty acid produced by certain gut bacteria, and it serves as a primary fuel source for the cells lining the colon. Without enough of it, those cells struggle to maintain a healthy barrier and to regulate the fluid balance that keeps stool properly formed. The loss of butyrate producers is one of the more compelling mechanistic links between HCTZ and diarrhea, because butyrate depletion has been connected to loose stools in other clinical settings as well.

How HCTZ Compares to Other Blood Pressure Medications

Not all blood pressure drugs affect the gut the same way. The rat study that documented HCTZ’s impact on butyrate producers also compared it head-to-head with two other common antihypertensives: captopril (an ACE inhibitor) and amlodipine (a calcium channel blocker). All three drugs shifted the gut’s bacterial mix toward a higher proportion of anaerobic species, but that is roughly where the similarities ended.

Captopril and amlodipine both restored certain beneficial bacterial populations to levels seen in healthy control animals. They also reduced gut pathology, lowered intestinal permeability, and dialed back sympathetic nervous system activity in the gut. HCTZ did none of those things. It was unable to reduce neuroinflammation, gut sympathetic tone, or gut barrier impairment.³ In plain terms, while two of the three drugs appeared to leave the gut in better shape while lowering blood pressure, HCTZ lowered blood pressure while leaving gut health worse off.

This is worth noting for people who experience persistent GI trouble on HCTZ and wonder whether an alternative might agree with them better. While switching medications is always a conversation between you and your doctor, the research suggests that the gut burden is not identical across drug classes. If digestive symptoms are a problem, it is reasonable to ask whether a different first-line agent might achieve the same blood-pressure goal with fewer intestinal side effects.

When Combination Pills Complicate Matters

HCTZ is frequently prescribed not on its own but as part of a combination pill, bundled with an ACE inhibitor, an ARB (angiotensin receptor blocker), or a calcium channel blocker. These fixed-dose combinations simplify treatment by reducing the number of pills a patient takes daily, but they also make it harder to figure out which ingredient is responsible when side effects appear.

Two published case reports describe patients who were taking olmesartan together with hydrochlorothiazide and amlodipine and went on to develop serious intestinal conditions. One patient developed sprue-like enteropathy, a condition that mimics celiac disease with villous atrophy and chronic diarrhea. The other developed colitis.⁴ Olmesartan has a well-documented independent link to sprue-like enteropathy, which muddies the picture: was HCTZ contributing, or was olmesartan doing the damage alone? The honest answer is that in a three-drug pill, assigning blame to one component is extremely difficult.

The practical takeaway is that if you develop persistent or worsening diarrhea while taking a combination pill that includes HCTZ, the culprit could be HCTZ, one of its companion drugs, or the interaction between them. Sorting that out usually requires your doctor to try removing one component at a time, which is easier when the drugs are prescribed as separate pills rather than a single combination tablet.

The Electrolyte Angle

HCTZ’s core mechanism, blocking sodium and chloride reabsorption in the kidneys, inevitably changes the body’s electrolyte balance. Low potassium (hypokalemia) and low magnesium are the most frequently discussed consequences, but low sodium can also occur, especially at higher doses or in older adults. These electrolyte shifts can affect the gut in their own right.

Potassium and magnesium both play roles in smooth-muscle contraction, including the rhythmic contractions that move food through the intestines. When levels drop, motility can become erratic. Some people develop constipation; others experience cramping and loose stools. The relationship is not perfectly predictable, because it depends on how low levels actually fall and how sensitive a given person’s gut is to the shift. But if your diarrhea on HCTZ coincides with muscle cramps, fatigue, or an irregular heartbeat, electrolyte depletion is a plausible contributor and something your doctor can check with a simple blood draw.

What makes HCTZ-related electrolyte problems more than a theoretical concern is that they are not rare. Studies have consistently found that a meaningful proportion of patients on HCTZ develop potassium levels below the normal range, and the risk rises with dose and with the duration of treatment. Monitoring electrolytes periodically while on HCTZ is standard practice, but not every patient gets regular labs drawn, and subclinical drops can still cause symptoms.

The Dehydration Double Bind

Here is where HCTZ and diarrhea create a uniquely problematic feedback loop. HCTZ is a diuretic: it works by making your kidneys excrete more water and sodium than they normally would. If diarrhea develops on top of that, you are losing fluid from two directions at once, the kidneys and the gut. Dehydration sets in faster than it would in someone who was not already on a drug designed to remove water from the body.

Dehydration, in turn, can worsen the very electrolyte imbalances that HCTZ already tends to cause. As your body loses fluid, potassium and sodium concentrations swing further from their normal range. That can intensify the GI symptoms, creating a cycle in which diarrhea leads to dehydration leads to worse electrolyte problems leads to more gut dysfunction.

Older adults face a particularly steep version of this risk. Kidney function declines with age, the thirst mechanism becomes less reliable, and many elderly patients are already on multiple medications that affect fluid balance. A study of elderly patients found that certain antihypertensive medications were more frequently prescribed among those who were dehydrated, highlighting how common the overlap between these drugs and inadequate fluid status can be in older populations.⁵ If you are over 65 and taking HCTZ, even a day or two of diarrhea deserves prompt attention and deliberate rehydration, not a wait-and-see approach.

Other Digestive Side Effects Beyond Diarrhea

Diarrhea is only one item on HCTZ’s gastrointestinal menu. Nausea is probably more common, especially during the first week or two of use. Some people report stomach cramping without diarrhea, or a general loss of appetite that makes meals unappealing. Constipation can also occur, which sometimes surprises people who expect a drug that promotes fluid loss to push things the other direction.

At the more serious end of the spectrum, HCTZ has a rare but documented association with pancreatitis, inflammation of the pancreas. The mechanism is not fully understood, but it has been reported in enough cases to appear in prescribing information. Pancreatitis typically presents as severe upper-abdominal pain that radiates to the back, often with nausea and vomiting. It is uncommon enough that most patients on HCTZ will never experience it, but it is worth knowing about because it requires immediate medical attention.

Cholestatic jaundice, a type of liver dysfunction that impairs bile flow, is another rare but recognized complication. The hepatic effects of thiazide diuretics have been known for decades, and while they affect only a small fraction of users, they can cause GI symptoms like pale stools and nausea that a patient might initially mistake for a stomach bug.

Probiotics and the Emerging Research Frontier

Given the evidence that HCTZ disrupts the gut microbiome, researchers have started asking whether probiotics could offset some of that damage. A study in spontaneously hypertensive rats tested whether a specific probiotic strain (Limosilactobacillus fermentum CECT5716) could improve outcomes when given alongside HCTZ. The researchers found that while HCTZ lowered blood pressure, it disrupted the gut microbiota balance, and the probiotic appeared to enhance the antihypertensive response.⁶

This is early-stage research in animals, not a recommendation to start popping probiotic capsules alongside your blood pressure pill. But it points in an interesting direction. If HCTZ’s gut effects are partly mediated by changes in bacterial populations, then strategies aimed at supporting those populations could theoretically reduce GI side effects while preserving or even improving the drug’s blood-pressure benefit. For now, the evidence is too thin to draw clinical conclusions. But it is worth watching, especially for people who tolerate HCTZ’s blood-pressure effects well but struggle with its digestive consequences.

What is already clear from the animal data is that HCTZ’s relationship with the gut is not trivial or incidental. The drug does not simply pass through the digestive tract on its way to the kidneys. It actively reshapes the microbial landscape, weakens the intestinal barrier, and depletes the bacterial populations that produce compounds essential for colon health.² Whether future human studies confirm the same magnitude of effect remains to be seen, but the direction of the findings is consistent across multiple research groups and experimental models, and it aligns with what patients report in practice.